VETERANS HEALTH ADMINISTRATION
- Country
- 🇺🇸United States
- Ownership
- Private
- Established
- 1939-05-21
- Employees
- 101
- Market Cap
- -
Clinical Trials
205
Trial Phases
6 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (149 trials with phase data)• Click on a phase to view related trials
Supporting VETerans With Kidney Disease Through Food As Medicine
- Conditions
- Kidney DiseasesFood/Nutrition InsecurityDiabetesHypertension
- First Posted Date
- 2025-09-26
- Last Posted Date
- 2025-10-01
- Lead Sponsor
- VA Eastern Colorado Health Care System
- Target Recruit Count
- 20
- Registration Number
- NCT07194733
- Locations
- 🇺🇸
Rocky Mountain Regional VA Medical Center, Aurora, Colorado, United States
Pharmacist-Intensivist Collaborative Telehealth for Post-Intensive Care Syndrome
- Conditions
- Post Intensive Care Syndrome (PICS)
- First Posted Date
- 2025-05-21
- Last Posted Date
- 2025-09-23
- Lead Sponsor
- Malcom Randall VA Medical Center
- Target Recruit Count
- 24
- Registration Number
- NCT06983496
- Locations
- 🇺🇸
Malcom Randall Veterans Affairs Medical Center, Gainesville, Florida, United States
Telehealth-based Symptom Management for Veterans Treated With Selinexor
- Conditions
- Large-cell LymphomaMultiple Myeloma
- First Posted Date
- 2024-06-11
- Last Posted Date
- 2025-02-10
- Lead Sponsor
- Durham VA Medical Center
- Target Recruit Count
- 20
- Registration Number
- NCT06452446
- Locations
- 🇺🇸
Durham VA Medical Center, Durham, North Carolina, United States
Computerized Cognitive Behavioral Therapies for Suicide Prevention and Depression
- Conditions
- DepressionSuicide
- First Posted Date
- 2024-04-19
- Last Posted Date
- 2025-04-23
- Lead Sponsor
- VA Eastern Colorado Health Care System
- Target Recruit Count
- 472
- Registration Number
- NCT06375083
- Locations
- 🇺🇸
Eastern Colorado Health Care System, Aurora, Colorado, United States
The Medically Reproducing Bariatric Surgery (MRB) II Study
- Conditions
- Type 2 DiabetesObesity
- First Posted Date
- 2024-04-12
- Last Posted Date
- 2025-02-07
- Lead Sponsor
- Durham VA Medical Center
- Target Recruit Count
- 50
- Registration Number
- NCT06363747
- Locations
- 🇺🇸
Greenville VA Health Care Center, Greenville, North Carolina, United States
- Prev
- 1
- 2
- 3
- 4
- 5
- 41
- Next
News
COVID-19 Boosters Reduce Hospitalization Risk by 29% in Cancer Patients, Large Multi-Center Study Shows
A large retrospective study of over 161,000 cancer patients across four major U.S. health systems found that COVID-19 booster vaccines reduced hospitalizations and ICU admissions by 29%.
FDA Clears First Wireless, Catheter-Free Urodynamics System for Bladder Dysfunction Testing
The FDA has granted 510(k) clearance to Bright Uro's Glean™ Urodynamics System, the first wireless, catheter-free device for monitoring bladder dysfunction in patients with lower urinary tract conditions.
Pharmacist Feedback Enhances Heart Failure Medication Management in Veterans
A study at AHA 2024 reveals that pharmacists in the VHA system, when given feedback on heart failure medication rates, increased their management and adjustment of these medications.
Cellworks Biosimulation Platform Predicts Chemotherapy Benefit in NSCLC Patients Beyond PD-L1 Status
Cellworks' biosimulation platform accurately predicted overall survival and chemotherapy benefit in two real-world NSCLC patient cohorts, advancing personalized cancer treatment beyond traditional PD-L1 biomarkers.
Global Experts Share Strategies to Enhance Lung Cancer Screening Access and Early Detection
Healthcare experts at the 2024 World Conference on Lung Cancer presented innovative approaches to improve lung cancer screening uptake, emphasizing the need for tailored recruitment strategies and digital solutions.
First Veteran Receives FDA-Approved Qalsody for SOD1-ALS at Houston VA Medical Center
Roy Swearingen, a 65-year-old Marine Corps veteran from Texas, became the first veteran in the United States to receive Qalsody, an FDA-approved medication for SOD1-mutated ALS.